{"id":5526,"date":"2019-07-23T15:20:33","date_gmt":"2019-07-23T09:50:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5526"},"modified":"2021-07-24T12:57:28","modified_gmt":"2021-07-24T07:27:28","slug":"recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","title":{"rendered":"FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a43e1b7a9084\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a43e1b7a9084\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\/#Generic_Lyrica_FDA_nods_to_first_generic_alternatives_to_Pfizers_Lyrica\" >Generic Lyrica: FDA nods to first generic alternatives to Pfizer\u2019s Lyrica<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\/#CRH_Medical_Corporation_acquires_a_majority_stake_in_Crystal_River_Anesthesia\" >CRH Medical Corporation acquires a majority stake in Crystal River Anesthesia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\/#Baxters_Myxredlin-_the_first_and_only_Ready-To-Use_Insulin_for_IV_Infusion_wins_FDA_approval\" >Baxter\u2019s Myxredlin- the first and only Ready-To-Use Insulin for IV Infusion wins FDA approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\/#Salarius_Pharmaceuticals_announces_the_closing_of_Strategic_Merger_with_Flex_Pharma\" >Salarius Pharmaceuticals announces the closing of Strategic Merger with Flex Pharma<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Generic_Lyrica_FDA_nods_to_first_generic_alternatives_to_Pfizers_Lyrica\"><\/span><strong>Generic Lyrica: FDA nods to first generic alternatives to Pfizer\u2019s Lyrica<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p> The U.S. FDA has approved the <strong>first generic substitute of Pfizer\u2019s Lyrica (pregabalin)<\/strong> in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the Pfizer, whose patent expired on December 30, 2018. Another six-month extension of the patent further delayed the launch of generic versions of the drug. <br>The approval of nine generic versions of the drug, Lyrica, is for the administration in patients struggling <strong>with neuropathic pain associated with<a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-peripheral-neuropathy-pipeline-insight\"> diabetic peripheral neuropathy<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/postherpetic-neuralgia-market\">postherpetic neuralgia<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/fibromyalgia-market\">fibromyalgia <\/a>and neuropathic pain associated with spinal cord injury. <\/strong>Lyrica is also used as adjunctive therapy for the treatment of partial-onset seizures. Pharma giants namely Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy\u2019s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals received the approval of the drug. The drug, however, is dispensed with utmost care as it may cause some grave allergic reactions, and can even result in suicidal thoughts in a small number of patients. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"CRH_Medical_Corporation_acquires_a_majority_stake_in_Crystal_River_Anesthesia\"><\/span><strong>CRH Medical Corporation acquires a majority stake in Crystal River Anesthesia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>CRH Medical Corporation, a service provider of anesthesia services within Gastroenterology (G.I.), <strong>has acquired 51% interest in Crystal River Anesthesia Associates,<\/strong> LLC. Crystal River is a Florida-based medical group practice ensuring anesthesia services to two G.I. ambulatory surgery centres with n estimated revenue of USD 1.6 Million annually. The transaction was financed through an amalgamation of CRH\u2019s credit facility and cash on hand. The acquisition of Crystal River marks the fifth anesthesia acquisition of CRH in the state of Florida and 23rd in the USA. <br>CRH Medical Corporation is a North American based commercial healthcare company exclusively focused on providing innovative products and services for advancing gastrointestinal diseases therapy market. <br><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Baxters_Myxredlin-_the_first_and_only_Ready-To-Use_Insulin_for_IV_Infusion_wins_FDA_approval\"><\/span><strong>Baxter\u2019s Myxredlin- the first and only Ready-To-Use Insulin for IV Infusion wins FDA approval <\/strong><br><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Baxter has won FDA\u2019s approval for <strong>Myxredlin \u2013 the first ready-to-use insulin for IV infusion.<\/strong> The product is an insulin human in 0.9% sodium chloride Injection administered as short-acting human insulin to improve glycemic control in pediatric patients living with diabetes mellitus and adults. <br>Myxredlin comes with an extended shelf life of 30 days at room temperature and if refrigerated, for 24 months enclosed in a carton to protect from light. Administered in a standardized concentration of 100 units\/100 mL in a flexible plastic container ensures a consistent, steady concentration with every administration, which along with guaranteeing patient safety, helps streamline workflow for pharmacists and nurses in acute care settings. <br><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Salarius_Pharmaceuticals_announces_the_closing_of_Strategic_Merger_with_Flex_Pharma\"><\/span><strong>Salarius Pharmaceuticals announces the closing of Strategic Merger with Flex Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Salarius Pharmaceuticals, a pharma company targeting epigenetic causes of <a href=\"https:\/\/www.delveinsight.com\/report-store\/thymus-cancer-market\">cancers<\/a>, has announced <strong>the conclusion of its merger with a wholly-owned subsidiary, Flex Pharma. <\/strong>After the completion of the definitive merger agreement, started in January 2019, Flex Pharma will now operate as Salarius Pharmaceuticals, Inc. The combined entities will work to advance further the clinical pipeline of Salarius to target rare, orphan cancers, which at present lack standard treatment therapy. <br>Salarius Pharmaceuticals, in a private placement, recently completed USD 6.4 Million which the company plans to use for the management of the combined company along with the cash influx from Flex Pharma. After the final transaction, <strong>Flex Pharma will hold 19.9% whereas the Salarius will own the remaining 80.1% of the combined entity. <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Generic Lyrica: FDA nods to first generic alternatives to Pfizer\u2019s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer\u2019s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the Pfizer, whose patent expired on December [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5527,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1728,683,639],"industry":[17226,17225],"therapeutic_areas":[17240,17245,17228],"class_list":["post-5526","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ipo","tag-mergers-and-acquisitions","tag-pharma-news","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lyrica&#039;s generic; Flex &amp; Salarius&#039;s merger; FDA&#039;s nod to Myxredlin;<\/title>\n<meta name=\"description\" content=\"Baxter has won FDA\u2019s approval for Myxredlin \u2013 the first ready-to-use insulin for IV infusion. The product is an insulin human in 0.9% sodium chloride...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyrica&#039;s generic; Flex &amp; Salarius&#039;s merger; FDA&#039;s nod to Myxredlin;\" \/>\n<meta property=\"og:description\" content=\"Baxter has won FDA\u2019s approval for Myxredlin \u2013 the first ready-to-use insulin for IV infusion. The product is an insulin human in 0.9% sodium chloride...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-23T09:50:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lyrica's generic; Flex & Salarius's merger; FDA's nod to Myxredlin;","description":"Baxter has won FDA\u2019s approval for Myxredlin \u2013 the first ready-to-use insulin for IV infusion. The product is an insulin human in 0.9% sodium chloride...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","og_locale":"en_US","og_type":"article","og_title":"Lyrica's generic; Flex & Salarius's merger; FDA's nod to Myxredlin;","og_description":"Baxter has won FDA\u2019s approval for Myxredlin \u2013 the first ready-to-use insulin for IV infusion. The product is an insulin human in 0.9% sodium chloride...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-23T09:50:33+00:00","article_modified_time":"2021-07-24T07:27:28+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter","name":"Lyrica's generic; Flex & Salarius's merger; FDA's nod to Myxredlin;","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News.png","datePublished":"2019-07-23T09:50:33+00:00","dateModified":"2021-07-24T07:27:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Baxter has won FDA\u2019s approval for Myxredlin \u2013 the first ready-to-use insulin for IV infusion. The product is an insulin human in 0.9% sodium chloride...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-pfizer-salarius-crystal-crh-baxter#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News.png","width":750,"height":410,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/09021042\/Recent-Pharma-News-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Mergers and Acquisitions<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 23, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 23, 2019 3:20 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5526"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5526\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5527"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5526"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5526"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}